Semaglutide guide
Why can weight change plateau on Semaglutide?
How to interpret a plateau without assuming a dose problem, treatment failure, or a reason to add products.
In brief
A plateau is a description of a weight trend, not a diagnosis of resistance or a reason to make an independent medication change. Trial averages show trajectories over time, but they do not identify the cause of a plateau for one person or validate online strategies for breaking it.
Why this question comes up
A concern worth understanding clearly
When a weight trend slows or stops changing, it is natural to look for a single explanation. A plateau is a pattern to discuss in context, not proof of resistance or a reason to change a medicine without clinical guidance.
Research context
What research can tell us
Body weight is influenced by energy intake, expenditure, body composition, adherence, illness, other medicines, fluid shifts, measurement timing, and many other factors. A medication mechanism does not isolate which factor explains an individual's trend.
What has been studied
What this cannot answer
Semaglutide trials report group-average weight trajectories
The STEP 1 trial provides controlled evidence of average weight outcomes over time in a defined population receiving a studied intervention and lifestyle program.
How to interpret it: A trial curve is context, not a rule for a person's week-to-week scale changes.
Study limits
- Average trajectories do not explain individual plateaus
- The trial is not evidence for self-directed changes, combinations, or product substitutions
What this cannot answer
- Scale weight alone does not identify fat, lean tissue, water, or a medical cause.
- Popular ‘plateau breakers’ are not controlled evidence and can create safety risk.
Safety and uncertainty
When this needs medical help
What is known
- FDA-approved semaglutide labels describe gastrointestinal adverse reactions; the exact warning and contraindication context depends on the product label.
Seek urgent care when
- Severe or persistent abdominal symptoms, repeated vomiting, symptoms of dehydration, or a suspected severe allergic reaction need prompt medical assessment rather than online troubleshooting.
What remains unknown
- A second-hand report cannot establish the identity, concentration, sterility, cause, or clinical significance of symptoms for another person.
When to contact a clinician
A clinician should assess a sustained concern about response, symptoms, nutrition, glucose, other medicines, or treatment goals; the correct next step may differ substantially between individuals.
Need help understanding this information?Continue exploring
Questions you may still have
These guides add useful context without replacing personal medical advice.
Common follow-ups
More questions, answered carefully
Does a plateau prove the medicine stopped working?
No. It is a pattern that needs context and cannot be explained from a chart or a second-hand report alone.
Does this page recommend adding another medicine or peptide?
No. It does not recommend combinations, switching, or self-directed changes.
Sources
Sources you can check
Last reviewed 2026-08-06. These links show the studies, prescribing information, and regulator material used for this page.
- 1. Once-Weekly Semaglutide in Adults with Overweight or Obesity
The New England Journal of Medicine / PubMed - Accessed 2026-08-06 - Supports: weight-management trial context, average outcomes, response variability
- 2. WEGOVY (semaglutide) prescribing information
U.S. Food and Drug Administration - Accessed 2026-08-06 - Supports: approved-use context, mechanism, warnings, adverse reactions